Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" From Analysts
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" From Analysts
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) have been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $53.92.
据市场评级公司报道,Kymera治疗公司(纳斯达克代码:KYMR-GET评级)的股票已被目前覆盖该公司的13家研究公司的共识评级定为“中等买入”。3名研究分析师对该股的评级为持有,9名分析师对该公司的评级为买入。在过去一年对该股进行评级的分析师中,12个月目标价的平均水平为53.92美元。
Several research analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, August 15th. They issued a "buy" rating and a $40.00 price target on the stock. Credit Suisse Group raised their price target on shares of Kymera Therapeutics from $60.00 to $61.00 and gave the company an "outperform" rating in a report on Wednesday, August 10th. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $35.00 to $37.00 and gave the company an "equal weight" rating in a report on Monday, August 29th. SVB Leerink initiated coverage on shares of Kymera Therapeutics in a research note on Wednesday, July 20th. They set a "market perform" rating and a $26.00 price objective on the stock. Finally, Wells Fargo & Company dropped their price objective on shares of Kymera Therapeutics from $62.00 to $35.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 1st.
几位研究分析师最近对该股发表了评论。杰富瑞金融集团在8月15日星期一的一份报告中对Kymera治疗公司的股票进行了报道。他们对该股给予了“买入”评级和40.00美元的目标价。瑞士信贷集团在8月10日(周三)的一份报告中将Kymera治疗公司的股票目标价从60.00美元上调至61.00美元,并给予该公司“跑赢大盘”的评级。在8月29日周一的一份报告中,摩根士丹利将Kymera治疗公司的股票目标价从35.00美元上调至37.00美元,并给予该公司“同等权重”的评级。SVB Leerink在7月20日星期三的一份研究报告中开始报道Kymera Treateutics的股票。他们为该股设定了“市场表现”评级和26.00美元的目标价。最后,富国银行将Kymera治疗公司股票的目标价从62.00美元下调至35.00美元,并在6月1日星期三的一份研究报告中对该股设定了“增持”评级。
Kymera Therapeutics Stock Performance
Kymera治疗公司股票表现
KYMR opened at $21.69 on Monday. The company's 50 day simple moving average is $27.34 and its 200 day simple moving average is $26.73. Kymera Therapeutics has a 1 year low of $13.15 and a 1 year high of $69.12. The stock has a market capitalization of $1.19 billion, a PE ratio of -8.00 and a beta of 0.99.
KYMR周一开盘报21.69美元。该公司的50日简单移动均线切入位为27.34美元,200日简单移动均线切入位为26.73美元。Kymera治疗公司的一年低点为13.15美元,一年高位为69.12美元。该股市值11.9亿美元,市盈率为-8.00,贝塔系数为0.99。
Insider Transactions at Kymera Therapeutics
Kymera治疗公司的内幕交易
In related news, Director Bvf Partners L. P/Il purchased 545,525 shares of the firm's stock in a transaction dated Monday, August 22nd. The stock was acquired at an average price of $26.00 per share, with a total value of $14,183,650.00. Following the completion of the transaction, the director now owns 2,480,742 shares of the company's stock, valued at $64,499,292. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 17.01% of the company's stock.
在相关新闻中,董事Bvf Partners L.P/Il在8月22日(星期一)的交易中购买了该公司545,525股股票。该股是以每股26.00美元的平均价格收购的,总价值为14,183,650.00美元。交易完成后,董事现在拥有2480,742股该公司的股票,价值64,499,292美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接。公司内部人士持有该公司17.01%的股份。
Institutional Trading of Kymera Therapeutics
Kymera治疗公司的机构交易
A number of hedge funds have recently made changes to their positions in KYMR. Nisa Investment Advisors LLC grew its position in shares of Kymera Therapeutics by 338.8% during the second quarter. Nisa Investment Advisors LLC now owns 2,137 shares of the company's stock worth $42,000 after buying an additional 1,650 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Kymera Therapeutics during the first quarter valued at $53,000. Virtus ETF Advisers LLC increased its stake in Kymera Therapeutics by 147.4% during the second quarter. Virtus ETF Advisers LLC now owns 7,171 shares of the company's stock valued at $141,000 after purchasing an additional 4,273 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Kymera Therapeutics by 14.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,760 shares of the company's stock worth $159,000 after purchasing an additional 488 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Kymera Therapeutics during the second quarter worth $217,000.
一些对冲基金最近改变了他们在KYMR的头寸。NISA Investment Advisors LLC在第二季度将其在Kymera Treateutics的股票头寸增加了338.8%。NISA Investment Advisors LLC现在持有该公司2,137股股票,价值42,000美元,上个季度又购买了1,650股。Point72 Hong Kong Ltd在第一季度购买了Kymera Treeutics的新股份,价值53,000美元。Virtus ETF Advisers LLC在第二季度将其在Kymera治疗公司的股份增加了147.4%。Virtus ETF Advisers LLC在上个季度额外购买了4273股后,现在拥有7171股该公司的股票,价值14.1万美元。Zurcher Kantonalbank苏黎世广东银行在第一季度增持Kymera治疗公司股票14.9%。Zurcher Kantonalbank苏黎世广东银行在此期间额外购买了488股,现在拥有3,760股该公司股票,价值15.9万美元。最后,未来资产全球投资有限公司在第二季度收购了价值21.7万美元的Kymera治疗公司的新股份。
Kymera Therapeutics Company Profile
Kymera治疗公司简介
(Get Rating)
(获取评级)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Kymera治疗公司是一家生物制药公司,专注于发现和开发新型小分子疗法,这种疗法通过利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白质。它致力于开发IRAK4计划,该计划处于第一阶段临床试验,用于治疗免疫炎症疾病,包括化汗性汗腺炎、特应性皮炎、巨噬细胞激活综合征、泛发性脓疱性牛皮癣和类风湿性关节炎;IRAKIMiD计划,用于治疗MYD88突变的弥漫性大B细胞淋巴瘤;STAT3计划,用于治疗血液系统恶性肿瘤和实体瘤,以及自身免疫性疾病和纤维化;以及MDM2计划,用于治疗血液系统恶性肿瘤和实体瘤。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- 免费获取StockNews.com关于Kymera治疗公司(KYMR)的研究报告
- 卡特彼勒能否在下跌的市场中走得更高?
- Dave&Buster‘s能免受高通胀和低支出的影响吗?
- 这三只表现最好的中型股应该出现在你的观察名单上吗?
- 华尔街对Datadog的热情会带来巨大的收益吗?
- MarketBeat:回顾一周9/19-9/23
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Kymera治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kymera治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。